Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$938 Mln
Revenue (TTM)
$664 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
23.9
P/B Ratio
4
Industry P/E
28.32
EV/EBITDA
4.8
Div. Yield
0 %
Debt to Equity
3.3
Book Value
$--
EPS
$1.1
Face value
--
Shares outstanding
32,142,200
CFO
$612.07 Mln
EBITDA
$191.58 Mln
Net Profit
$-140.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
| 1.6 | 0.8 | -1.7 | -10.6 | 21.6 | 10.6 | 4.3 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
| -6.9 | 32.7 | 24.2 | -6.7 | -2.7 | 19.9 | -7.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
|
29.1 | 937.9 | 664.3 | 43.9 | 21.5 | 18.7 | 23.9 | 4.0 |
| 20.8 | 5,221.1 | 459.4 | 206.8 | 25.6 | 68.3 | 26 | 13.3 | |
| 31.4 | 3,857.8 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.9 | |
| 104.1 | 5,125.5 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 96.3 | |
| 56.2 | 10,961.9 | 2,937.8 | 523.9 | 23.2 | 9.3 | 21.2 | 1.9 | |
| 39.8 | 7,553.5 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 70.1 | 7,554.7 | 685.5 | 132.9 | 15.6 | 20.1 | 60.4 | 11.0 | |
| 13.8 | 6,858.7 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.4 | 1.1 | |
| 84.0 | 4,149.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.6 | 2.3 | |
| 8.9 | 10,539.7 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription... medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Read more
Co-Founder & Independent Chairman
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
Co-Founder & Independent Chairman
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
Headquarters
Stoughton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Collegium Pharmaceutical Inc (COLL) stood at $ 2,118 Mln as on 31-Mar-25
The share price of Collegium Pharmaceutical Inc (COLL) is $29.12 (NASDAQ) as of 13-Jun-2025 16:00 EDT. Collegium Pharmaceutical Inc (COLL) has given a return of 21.62% in the last 3 years.
Collegium Pharmaceutical Inc (COLL) has a market capitalisation of $ 938 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Collegium Pharmaceutical Inc (COLL) is 4.00 times as on 13-Jun-2025, a 17% discount to its peers’ median range of 4.84 times.
The P/E ratio of Collegium Pharmaceutical Inc (COLL) is 23.92 times as on 13-Jun-2025, a 16% discount to its peers’ median range of 28.32 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Collegium Pharmaceutical Inc (COLL) and enter the required number of quantities and click on buy to purchase the shares of Collegium Pharmaceutical Inc (COLL).
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
The CEO & director of Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.. is Collegium Pharmaceutical Inc (COLL), and CFO & Sr. VP is Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph..
There is no promoter pledging in Collegium Pharmaceutical Inc (COLL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,096
|
|
|
1,054
|
|
|
755
|
|
|
741
|
|
|
709
|
|
|
532
|
|
|
522
|
|
|
421
|
|
|
386
|
| Collegium Pharmaceutical Inc. (COLL) | Ratios |
|---|---|
|
Return on equity(%)
|
18.73
|
|
Operating margin(%)
|
21.45
|
|
Net Margin(%)
|
6.61
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Collegium Pharmaceutical Inc (COLL) was $0 Mln.
$-0.48
(
